Last winter the Intellectual Property Institute, London, published Extending Rewards for Innovative Drug Development - A Report on Supplementary Certificates for Pharmaceutical Products. According to the Institute: "This report contains an analysis of the impact of Supplementary Protection Certificates for medicinal products since their introduction in 1993. In particular, it assesses whether SPCs are still "fit for purpose" for the modern pharmaceutical industry. The Report contains a discussion of the aims of the SPC regime for medicinal products. Some of the significant cases for the drug development industry are placed in context, including the recent MIT/Gliadel and Yissum decisions and there is an overview of the new six month paediatric extensions for SPCs. The Report concludes with an assessment of the effect of SPCs on incentives to invest in pharmaceutical R&D".This report, specially prepared for the Institute by Duncan Curley, can be purchased directly from it in one of two formats: as a pdf version at £30 or in hard copy format at £48.
Following a request from the SPC Blog, the Institute has kindly agreed to make both the hard copy of this report and the pdf version available to SPC Blog readers at a handsome reduction, i.e. at £24 (in the case of hard copies, that's £24 plus P&P). If you would like to take advantage of this offer, email Anne Goldstein here and quote the special offer code "THESPCBLOG".
No comments:
Post a Comment